Wall Street Zen Downgrades KalVista Pharmaceuticals (NASDAQ:KALV) to Hold

KalVista Pharmaceuticals (NASDAQ:KALV) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Sunday.

KALV has been the subject of several other research reports. Needham & Company LLC increased their price target on shares of KalVista Pharmaceuticals from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Wednesday, March 25th. HC Wainwright lifted their price objective on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the stock a “buy” rating in a research report on Friday, January 9th. Citizens Jmp dropped their target price on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a research note on Thursday, March 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Thursday, January 22nd. Finally, Stifel Nicolaus raised their price target on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $32.60.

KalVista Pharmaceuticals Price Performance

KALV stock opened at $19.90 on Friday. The stock has a market cap of $1.02 billion, a price-to-earnings ratio of -5.04 and a beta of -0.40. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21. The company has a 50 day simple moving average of $16.44 and a 200 day simple moving average of $14.64. KalVista Pharmaceuticals has a 1 year low of $9.23 and a 1 year high of $21.31.

Insider Activity at KalVista Pharmaceuticals

In other news, insider Nicole Sweeny sold 3,975 shares of the business’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $15.57, for a total transaction of $61,890.75. Following the completion of the transaction, the insider directly owned 47,003 shares in the company, valued at $731,836.71. The trade was a 7.80% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Paul K. Audhya sold 5,354 shares of the stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $83,361.78. Following the completion of the sale, the insider owned 138,983 shares in the company, valued at $2,163,965.31. This trade represents a 3.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 248,009 shares of company stock valued at $4,213,467 in the last quarter. 4.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets boosted its position in shares of KalVista Pharmaceuticals by 47.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after acquiring an additional 1,292 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in KalVista Pharmaceuticals during the third quarter valued at approximately $55,000. Wolverine Asset Management LLC bought a new stake in KalVista Pharmaceuticals during the third quarter valued at approximately $57,000. Truvestments Capital LLC grew its stake in KalVista Pharmaceuticals by 253.8% in the 4th quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock worth $76,000 after buying an additional 3,360 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of KalVista Pharmaceuticals during the 3rd quarter valued at $63,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.